Resistance detected in PBMCs predicts virological rebound in HIV-1 suppressed patients switching treatment
Resistance detected in PBMCs predicts virological rebound in HIV-1 suppressed patients switching treatment
复制标题
DOI：
10.1016/j.jcv.2018.04.001
复制
发表时间：
2018-07-01
影响因子：
8.8
通讯作者：
Santoro, Maria Mercedes
中科院分区：
文献类型：
--
作者：
Armenia, Daniele;Zaccarelli, Mauro;Santoro, Maria Mercedes
Background: Genotypic resistance test (GRT) performed in peripheral blood mononuclear cells (PBMC) represents a chance to evaluate resistance in virologically suppressed HIV infected patients.Objectives: To evaluate the impact of baseline resistance detected through PBMC GRT on virological rebound after switching treatment.Study design: Baseline genotypic susceptibility scores (GSS) from PBMC GRT (DNA-GSS) and from previous cumulative plasma GRTs (when available, pRNA-GSS) were evaluated. Survival analysis was used to assess the probability and predictors of virological rebound (VR).Results: 227 virologically suppressed patients were analysed. Twenty-four months after switching therapy, the probability of VR was 15.3%. Patients showing an intermediate or full resistant DNA-GSS had a higher probability of experiencing VR compared to those carrying a fully susceptible DNA-GSS (27.2% vs. 13.7%, p = 0.001). By multivariable Cox regression, patients with an intermediate/full resistant DNA-GSS, with a nadir CD4 count
